BTIG Reiterates Buy Rating on Moonlake Immunotherapeutics (MLTX)

March 19, 2025 4:54 AM EDT Send to a Friend
BTIG analyst Julian Harrison reiterated a Buy rating and $81.00 price target on Moonlake Immunotherapeutics (NASDAQ: MLTX).The analyst comments "We ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login